International Oncology Network - Cancer & Hematology News
All Blog Posts Tagged 'ASCO-GI' (1)
Regorafenib Shows Statistically Significant Improvement in OS in Patients with mCRC Refractory to Standard Approved Therapies
The latest data on the investigational drug regorafenib (BAY 73-4506)from the Phase III CORRECT trial(Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) were presented at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI), in San Francisco, CA.
Regorafenib (BAY 73-4506) is an an investigational oral multi-kinase inhibitor developed by Bayer which targets angiogenic,…
Added by Peter Hofland, PhD on January 18, 2012 at 9:30am — No Comments
Latest Blog Posts
Most Popular Blog Posts
Monthly Archives
2013
2012
- December (32)
- November (19)
- October (17)
- September (9)
- August (10)
- July (4)
- June (29)
- May (16)
- April (6)
- March (4)
- February (21)
- January (38)
2011
- December (47)
- November (32)
- October (21)
- September (32)
- August (18)
- July (23)
- June (83)
- May (45)
- April (54)
- March (36)
- February (62)
- January (43)
2010
- December (58)
- November (49)
- October (65)
- September (23)
- August (7)
- July (4)
- June (34)
- May (7)
- April (7)
- March (5)
- February (3)
- January (6)
2009
2008
- December (19)
2007
- April (1)
2005
2004
- September (1)
2001
- November (1)
ADVERTISEMENT
Bookmark / Share
Join the Conversation!
© 2013 Created by Peter Hofland, PhD.
